APR March 2024 - 62

Pharmaceutical
P.I.N.
Points
Patent Innovation News
The purpose of this column is to highlight
and summarize recent key patents in the
pharmaceutical arena issued by the US
Patent Office in December, 2023.
Neelam Sharma, MS,
Lakshmi Lavanya Kundurthy, BE and
Hemant N. Joshi, Ph.D., MBA*
Tara Innovations, LLC
www.tarainnovations.com
*hemantjoshi@tarainnovations.com
Combination Therapies for
Treatment of BCMA-Related
Cancers and Autoimmune Disorders;
S.R. Riddell, D. Green, and T. Hill; Fred
Hutchinson Cancer Center, U.S.A; U.S.
Patent # 11,845,803; December 19, 2023.
B lymphocytes or B cells produce antibodies, which mediate
destruction of pathogens. B cells may contain molecules on their
surface such as B Cell Maturation Antigen (BCMA). BCMA binds to B
cell activation factor and a proliferation-inducing ligand, which lead
to NF-Kappa B activation. Uncontrolled proliferation of B cells may
result in cancer, autoimmune disease and inflammatory disease.
BCMA-specific chimeric antigen receptor (CAR) modified T cells
etc. can be used to treat B cell malignancies. The CAR comprises a
hydrophobic portion disposed between an extracellular component
and an intracellular component. The extracellular component
comprises a BCMA-specific binding domain and a therapeutically
effective amount of secretase inhibitor.
Eutectic Formulations of
Cyclobenzaprine Hydrochloride
and Amitriptyline Hydrochloride;
M. Nebuloni and P. Colombo; Tonix
Pharma Holdings, Dublin, IE; U.S.
Patent # 11,839,594; December 12, 2023.
The invention describes an eutectic of cyclobenzaprine HCl and
mannitol or Amitriptyline HCl and mannitol. Cyclobenzaprine
is a muscle relaxer used to treat muscle spasms. Amitryptyline
is a tricyclic antidepressant used to treat major depressive
disorder, a variety of pain syndromes such as neuropathic pain
fibromyalgia, and migraine. A eutectic system is a mixture of
chemical compounds that has a single chemical composition
that melts at a lower temperature than any other composition
made up of the same ingredients. These two actives have slow
absorption when administered orally. Also, these are unstable
in basic pH. Both problems could be solved by making eutectic
mixtures (75:25) with mannitol.
Compositions for Fecal Floral
Transplantation and Methods
for Making and Using Them and
Devices for Delivering Them;
T. J. Borody; Finch Therapeutics
Holding, USA; U.S. Patent # 11,850,269;
December 26, 2023.
Human flora, rather than just being waste material resulting
from digestion of food, is an important virtual organ containing
large numbers of living microorganisms. Bacteria makes 60%
of the dry masses of the feces. Infection of the bowel flora can
impact the health of the individual. The invention provides
compositions, e.g., formulations or preparations, and devices,
used for the transplantation of a treated or isolated fecal flora,
and methods for making and using them. Devices and methods
of the invention can be used for any gastric, gastrointestinal
and or colonic treatment or lavage. It can also be used for the
amelioration, stabilization, treatment and/or prevention of a
disease or a condition such as constipation, Crohn's Disease,
exposure to a poison or a toxin or for an infection.
62 |
| March 2024

http://www.tarainnovations.com

APR March 2024

Table of Contents for the Digital Edition of APR March 2024

Message from the Editor
Editorial Advisory Board
BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
An Interview with Dan Smithey, PhD President & CEO, Serán
FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
QC Corner - Enhancing Material and Equipment Availability in Production Isolators
BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
DRUG DELIVERY - Your Nails and You
DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
Event Preview - CPHI North America
Event Preview - Excipient World 2024
P.I.N. Points
Advertiser's Index
APR March 2024 - CoverTip01
APR March 2024 - CoverTip02
APR March 2024 - Cover1
APR March 2024 - Cover2
APR March 2024 - 1
APR March 2024 - 2
APR March 2024 - 3
APR March 2024 - 4
APR March 2024 - 5
APR March 2024 - Message from the Editor
APR March 2024 - Editorial Advisory Board
APR March 2024 - BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
APR March 2024 - 9
APR March 2024 - 10
APR March 2024 - 11
APR March 2024 - 12
APR March 2024 - 13
APR March 2024 - MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
APR March 2024 - 15
APR March 2024 - 16
APR March 2024 - 17
APR March 2024 - 18
APR March 2024 - FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
APR March 2024 - 20
APR March 2024 - 21
APR March 2024 - 22
APR March 2024 - 23
APR March 2024 - FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
APR March 2024 - 25
APR March 2024 - 26
APR March 2024 - 27
APR March 2024 - An Interview with Dan Smithey, PhD President & CEO, Serán
APR March 2024 - 29
APR March 2024 - 30
APR March 2024 - FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
APR March 2024 - 32
APR March 2024 - 33
APR March 2024 - QC Corner - Enhancing Material and Equipment Availability in Production Isolators
APR March 2024 - 35
APR March 2024 - BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
APR March 2024 - 37
APR March 2024 - 38
APR March 2024 - 39
APR March 2024 - Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
APR March 2024 - 41
APR March 2024 - MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
APR March 2024 - 43
APR March 2024 - Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
APR March 2024 - 45
APR March 2024 - 46
APR March 2024 - 47
APR March 2024 - DRUG DELIVERY - Your Nails and You
APR March 2024 - 49
APR March 2024 - 50
APR March 2024 - 51
APR March 2024 - DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
APR March 2024 - 53
APR March 2024 - 54
APR March 2024 - 55
APR March 2024 - FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
APR March 2024 - 57
APR March 2024 - Event Preview - CPHI North America
APR March 2024 - 59
APR March 2024 - Event Preview - Excipient World 2024
APR March 2024 - 61
APR March 2024 - P.I.N. Points
APR March 2024 - 63
APR March 2024 - Advertiser's Index
APR March 2024 - Cover3
APR March 2024 - Cover4
https://www.nxtbookmedia.com